NASDAQ:RGNX - REGENXBIO Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $62.86
Forecasted Upside: 96.67 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
2 Hold Ratings
4 Buy Ratings
1 Strong Buy Ratings

^$31.96 As of 08/2/2021 01:00 AM ET

▼ -0.36 (-1.11%)

1 month | 3 months | 12 months

Get New REGENXBIO Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for RGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGNX

^$62.86

▲ +96.67% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for REGENXBIO in the last 3 months. The average price target is $62.86, with a high forecast of $95.00 and a low forecast of $37.00. The average price target represents a 96.67% upside from the last price of $31.96.

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in REGENXBIO. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

1 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

2/9/2020

1 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/9/2020

0 strong buy ratings
4 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/7/2020

1 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/5/2020

1 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

2/3/2021

1 strong buy ratings
5 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

5/4/2021

1 strong buy ratings
4 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/3/2021

1 strong buy ratings
4 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/2/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/1/2021	Chardan Capital	Reiterated Rating	Buy		Low
3/8/2021	Morgan Stanley	Lower Price Target	Overweight	$67.00 ➝ $62.00	High
1/20/2021	Royal Bank of Canada	Boost Price Target	Neutral ➝ Sector Perform	$42.00 ➝ $50.00	High
1/19/2021	Morgan Stanley	Boost Price Target	Overweight	$51.00 ➝ $67.00	Low
1/6/2021	SVB Leerink	Boost Price Target	Market Perform	$34.00 ➝ $37.00	N/A
1/6/2021	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$60.00	N/A
12/15/2020	UBS Group	Initiated Coverage	Buy	$57.00	Low
11/11/2020	Morgan Stanley	Lower Price Target	Overweight	$55.00 ➝ $51.00	Medium
11/5/2020	SVB Leerink	Lower Price Target	Market Perform	$32.00 ➝ $31.00	High
9/24/2020	Barclays	Lower Price Target	Positive ➝ Overweight	$88.00 ➝ $79.00	High
8/25/2020	Raymond James	Reiterated Rating	Buy		High
8/14/2020	Chardan Capital	Reiterated Rating	Buy	$95.00	High
8/10/2020	Morgan Stanley	Lower Price Target	Overweight	$56.00 ➝ $55.00	Medium
8/4/2020	Chardan Capital	Reiterated Rating	Buy	$100.00	Medium
6/25/2020	Bank of America	Initiated Coverage	Buy	$60.00	High
6/7/2020	Chardan Capital	Reiterated Rating	Buy		Low
5/12/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$42.00	High
5/11/2020	Morgan Stanley	Boost Price Target	Overweight	$55.00 ➝ $56.00	High
4/22/2020	Chardan Capital	Reiterated Rating	Buy	$150.00	High
3/3/2020	Morgan Stanley	Lower Price Target	Overweight	$58.00 ➝ $55.00	High
1/29/2020	Chardan Capital	Reiterated Rating	Buy	$150.00	Low
1/17/2020	Morgan Stanley	Boost Price Target	Overweight	$55.00 ➝ $58.00	High
12/18/2019	Chardan Capital	Reiterated Rating	Buy	$150.00	Low
11/11/2019	Evercore ISI	Reiterated Rating	Buy	$65.00	High
10/11/2019	Morgan Stanley	Lower Price Target	Overweight	$85.00 ➝ $59.00	Low
9/4/2019	Chardan Capital	Set Price Target	Buy	$150.00	Low
8/21/2019	Chardan Capital	Set Price Target	Buy	$150.00	Medium
8/20/2019	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$38.00 ➝ $37.00	High
8/7/2019	Evercore ISI	Set Price Target	Buy	$79.00	High
7/15/2019	Morgan Stanley	Set Price Target	Buy	$84.00	High
6/18/2019	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $150.00	Medium
6/13/2019	Raymond James	Initiated Coverage	Outperform ➝ Outperform		High
6/5/2019	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$127.50 ➝ $145.00	Low
2/25/2019	Evercore ISI	Upgrade	In-Line ➝ Outperform	$51.25	High
2/5/2019	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$94.00	High
1/4/2019	Chardan Capital	Reiterated Rating	Buy	$127.50	High
12/19/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$93.00 ➝ $85.00	High
12/18/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$83.00 ➝ $88.00	High
12/17/2018	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$127.50	High
11/27/2018	SVB Leerink	Initiated Coverage	Underperform	$42.00	Low
11/8/2018	Bank of America	Boost Price Target	Neutral	$76.00 ➝ $84.00	High
11/8/2018	Raymond James	Set Price Target	Buy	$96.00	High
10/29/2018	Raymond James	Reiterated Rating	Buy		High
9/7/2018	Raymond James	Boost Price Target	Outperform ➝ Outperform	$76.00 ➝ $96.00	Low
8/13/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $83.00	Medium
8/8/2018	Chardan Capital	Lower Price Target	Buy	$130.00 ➝ $127.50	High
7/23/2018	Bank of America	Downgrade	Buy ➝ Neutral	$64.00 ➝ $80.00	Medium
7/16/2018	Chardan Capital	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $130.00	High
7/13/2018	Morgan Stanley	Boost Price Target	Overweight	$37.00 ➝ $92.00	Medium
7/10/2018	Chardan Capital	Boost Price Target	Buy ➝ Buy	$90.00 ➝ $130.00	Medium
6/25/2018	Raymond James	Reiterated Rating	Buy	$76.00	High
5/9/2018	Barclays	Reiterated Rating	Overweight ➝ Overweight	$38.00 ➝ $48.00	High
5/8/2018	Raymond James	Set Price Target	Buy	$45.00	High
4/11/2018	Raymond James	Set Price Target	Buy	$45.00	Low
4/9/2018	Chardan Capital	Boost Price Target	Buy ➝ Buy	$85.00 ➝ $90.00	High
3/14/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$36.00 ➝ $35.00	Low
2/12/2018	Mizuho	Initiated Coverage	Neutral ➝ Neutral	$28.00	Low
1/5/2018	Raymond James	Reiterated Rating	Buy		High
12/11/2017	Chardan Capital	Reiterated Rating	Buy		High
11/22/2017	Barclays	Initiated Coverage	Overweight	$38.00	N/A
11/9/2017	Morgan Stanley	Reiterated Rating	Overweight ➝ Overweight	$34.00	N/A
11/9/2017	Chardan Capital	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $85.00	N/A
10/12/2017	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$39.00	N/A
10/9/2017	Bank of America	Reiterated Rating	Buy	$33.00 ➝ $38.00	N/A
9/21/2017	Bank of America	Boost Price Target	Buy	$29.00 ➝ $33.00	Low
9/5/2017	Chardan Capital	Reiterated Rating	Buy	$55.00 ➝ $75.00	High
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$25.00	High
8/9/2017	Chardan Capital	Boost Price Target	Buy	$50.00 ➝ $55.00	High
4/11/2017	Chardan Capital	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00	High
11/13/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$25.00	N/A
10/10/2016	Piper Jaffray Companies	Set Price Target	Buy	$25.00	N/A
8/22/2016	Chardan Capital	Reiterated Rating	Buy		N/A
8/18/2016	Piper Jaffray Companies	Set Price Target	Buy	$25.00	N/A

(Data available from 8/3/2016 forward)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Today's Range

Now: $31.96

$31.89

$33.56

50 Day Range

MA: $36.69

$31.96

$40.48

52 Week Range

Now: $31.96

$25.92

$50.26

Volume

467,283 shs

Average Volume

385,188 shs

Market Capitalization

$1.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of REGENXBIO?

The following Wall Street sell-side analysts have issued stock ratings on REGENXBIO in the last twelve months: Barclays PLC, Chardan Capital, Morgan Stanley, Raymond James, Royal Bank of Canada, SVB Leerink LLC, TheStreet, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for RGNX.

What is the current price target for REGENXBIO?

7 Wall Street analysts have set twelve-month price targets for REGENXBIO in the last year. Their average twelve-month price target is $62.86, suggesting a possible upside of 96.7%. Chardan Capital has the highest price target set, predicting RGNX will reach $95.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $37.00 for REGENXBIO in the next year.
View the latest price targets for RGNX.

What is the current consensus analyst rating for REGENXBIO?

REGENXBIO currently has 2 hold ratings, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RGNX will outperform the market and that investors should add to their positions of REGENXBIO.
View the latest ratings for RGNX.

What other companies compete with REGENXBIO?

Other companies that are similar to REGENXBIO include Exelixis, Adaptive Biotechnologies, Recursion Pharmaceuticals, Vir Biotechnology, Abcam, Kodiak Sciences, SpringWorks Therapeutics, Ablynx, Iovance Biotherapeutics, Allogene Therapeutics, Sana Biotechnology, Relay Therapeutics, BioCryst Pharmaceuticals, Editas Medicine and NanoString Technologies.

How do I contact REGENXBIO's investor relations team?

REGENXBIO's physical mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is (240) 552-8181 and its investor relations email address is [email protected] The official website for REGENXBIO is www.regenxbio.com.